Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib. An Observational Multicentric Study.
Phase of Trial: Phase IV
Latest Information Update: 30 Jan 2014
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Biomarker; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 25 Jul 2013 Planned End Date changed from 1 Feb 2020 to 1 Sep 2020 as reported by ClinicalTrials.gov.
- 25 Jul 2013 Planned initiation date changed from 1 Feb 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.